{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:24:19Z","timestamp":1791973459072,"version":"4.4.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T00:00:00Z","timestamp":1513900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,5,31]]},"DOI":"10.2217\/fon-2017-0616","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T09:49:57Z","timestamp":1513936197000},"page":"1035-1047","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":70,"title":["Isatuximab Plus Pomalidomide\/Dexamethasone Versus Pomalidomide\/Dexamethasone in Relapsed\/Refractory Multiple Myeloma: Icaria Phase Iii Study Design"],"prefix":"10.1080","volume":"14","author":[{"given":"Paul G","family":"Richardson","sequence":"first","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA02215-5450, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Campana","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Le-Guennec","sequence":"additional","affiliation":[{"name":"Sanofi, Vitry-Alfortville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Min","family":"Hui","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Risse","sequence":"additional","affiliation":[{"name":"Sanofi, Vitry-Alfortville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Corzo","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C","family":"Anderson","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA02215-5450, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.15"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2017.05.005"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e3283565c56"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538835"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-392522"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3352"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422683"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.236"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.77"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.7934"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2679"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.356"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00197-0"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00035.2007"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.08.004"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192"},{"key":"e_1_3_3_32_1","volume-title":"58th ASH Annual Meeting & Exposition","author":"Moreno L","year":"2016","unstructured":"Moreno L , ZabaletaA, AlignaniDet al. Critical analysis on the mechanism of action (MoA) of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma (MM). Presented at: 58th ASH Annual Meeting & Exposition. CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740787"},{"key":"e_1_3_3_34_1","volume-title":"105th Annual Meeting of the American Association for Cancer Research","author":"Zhang B","year":"2014","unstructured":"Zhang B , YangG, DaiSet al. SAR650984, a humanized anti-CD38 antibody potently modulates intracellular and extracellular nucleotide levels of cancer cells. Presented at: 105th Annual Meeting of the American Association for Cancer Research. CA, USA, 5\u20139 April 2014."},{"key":"e_1_3_3_35_1","volume-title":"American Association for Cancer Research 104th Annual Meeting","author":"Wetzel M-C","year":"2013","unstructured":"Wetzel M-C , NicolazziC, Vall\u00e9eFet al. SAR650984: characterization of a potent Phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies. Presented at: American Association for Cancer Research 104th Annual Meeting. DC, USA, 6\u201310 April 2013."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.11.010"},{"issue":"2","key":"e_1_3_3_37_1","first-page":"606","article-title":"Increase of regulatory T cells in the peripheral blood of cancer patients","volume":"9","author":"Wolf AM","year":"2003","unstructured":"Wolf AM , WolfD, SteurerM, GastlG, GunsiliusE, Grubeck-LoebensteinB. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res.9(2), 606\u2013612 (2003).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.240"},{"key":"e_1_3_3_39_1","volume-title":"American Society of Clinical Oncology 50th Annual Meeting","author":"Martin TG","year":"2014","unstructured":"Martin TG , HsuK, StricklandSA, GlennMJ, MikhaelJ, CharpentierE. A Phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. Presented at: American Society of Clinical Oncology 50th Annual Meeting. IL, USA, 30 May\u20133 June 2014."},{"key":"e_1_3_3_40_1","volume-title":"The American Society of Clinical Oncology 52nd Annual Meeting","author":"Richter JR","year":"2016","unstructured":"Richter JR , MartinTG, VijRet al. Updated data from a Phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed\/refractory multiple myeloma (RRMM). Presented at: The American Society of Clinical Oncology 52nd Annual Meeting. IL, USA, 3\u20137 June 2016."},{"key":"e_1_3_3_41_1","volume-title":"American Society of Hematology 58th Annual Meeting & Exposition","author":"Martin TG","year":"2016","unstructured":"Martin TG , MannisGN, ChariAet al. Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple myeloma. Presented at: American Society of Hematology 58th Annual Meeting & Exposition. CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_3_42_1","volume-title":"American Society of Clinical Oncology 2017 Annual Meeting","author":"Mikhael J","year":"2017","unstructured":"Mikhael J , RichardsonPG, UsmaniSZet al. A Phase Ib study of isatuximab in combination with pomalidomide (Pom) and dexamethasone (Dex) in relapsed\/refractory multiple myeloma (RRMM). Presented at: American Society of Clinical Oncology 2017 Annual Meeting. IL, USA, 2\u20136 June 2017."},{"key":"e_1_3_3_43_1","volume-title":"16th International Myeloma Workshop 2017","author":"Richardson P","year":"2017","unstructured":"Richardson P , MikhaelJ, UsmaniSet al. Preliminary results from a Phase 1b study of isatuximab in combination with pomalidomide (Pom) and dexamethasone (dex) in relapsed\/refractory multiple myeloma. Presented at: 16th International Myeloma Workshop 2017. New Delhi, India, 1\u20134 March 2017."},{"key":"e_1_3_3_44_1","volume-title":"American Society of Hematology 58th Annual Meeting & Exposition","author":"Richardson PG","year":"2016","unstructured":"Richardson PG , MikhaelJ, UsmaniSZet al. Preliminary results from a Phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Presented at: American Society of Hematology 58th Annual Meeting & Exposition. CA, USA, 3\u20136 December 2016."},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0104"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.125864"},{"key":"e_1_3_3_48_1","volume-title":"22nd Congress of the European Hematology Association","author":"Mikhael J","year":"2017","unstructured":"Mikhael J , RichardsonP, UsmaniSet al. A Phase Ib study of isatuximab plus pomalidomide (Pom) and dexamethasone (dex) in relapsed\/refractory multiple myeloma (RRMM). Presented at: 22nd Congress of the European Hematology Association. Madrid, Spain, 22\u201325 June 2017."},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.8016"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612069"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0229"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:08Z","timestamp":1719125108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,22]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,5,31]]}},"alternative-id":["10.2217\/fon-2017-0616"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0616","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}